AcoMed Holdings Limited and Boston Scientific Corporation Announce Partial Tender Offer and Strategic Collaboration

Acandis Holding Limited (the “Company”, stock code: 6669.HK) and Boston Scientific Corporation (“Boston Scientific”, stock ticker: NYSE:BSX) are pleased to announce their partial acquisition offer and collaboration.

Pursuant to the offer, subject to certain preconditions being satisfied or waived by the offeree (Boston Scientific), the offeror will acquire up to 203,702,962 shares in the Company at a cash price of HK$20 per share, thereby obtaining up to a 65% equity interest in the Company (the “Partial Offer”). As of the date of this announcement, the Company has 313,389,171 issued shares. Based on the offer price of HK$20 per share, this represents a premium of approximately 99.4% over the average closing price of HK$10.03 for the 30 consecutive trading days ended December 9, 2022.

The offer value is i) approximately HK$3,134,518,500 (calculated on the assumption that the minimum number of shares required to make the offer effective by the closing date are tendered in acceptance, namely 156,725,925 shares (representing 50.01% of the total issued shares)); or ii) approximately HK$4,074,059,240 (calculated on the assumption that the maximum number of shares required to make the offer effective by the closing date are tendered in acceptance, namely 203,702,962 shares (representing 65% of the total issued shares)).

As of the date of this announcement, the Offeror has received irrevocable commitment letters from IU shareholders, committing to sell or procure the valid acceptance of the offer for shares representing approximately 55.14% to 60.14% of the total issued shares.

Upon completion of the transaction, the offeror intends to maintain the Company’s listing status on The Stock Exchange of Hong Kong Limited. The Company will also continue to operate in the market under its distinct brand identity and culture of “Acandis,” managed by the existing Chief Executive Officer, Li Jing.

Upon completion of the tender offer, the Company will further explore and establish commercial collaborations with Boston Scientific in China, enabling more physicians and patients to benefit from a more comprehensive product portfolio post-merger. Meanwhile, Boston Scientific may evaluate opportunities to register and market relevant products in global markets, including the United States, through collaboration with the Company. Additionally, the Company’s R&D and manufacturing facilities will support Boston Scientific in expanding its production and research and development operations, jointly identifying and developing products in potential new areas for each party or both parties, thereby creating extensive growth opportunities and significant strategic value for both sides.

Acotec is a globally leading innovative medical technology company, dedicated to the research, development, and application of technological platforms in the field of vascular interventional therapy. Leveraging its four proprietary technology platforms—drug-coating technology, radiofrequency ablation technology, polymer material technology, and aspiration platform technology—Acotec adheres to the philosophy of trustworthy innovation. It continuously addresses unmet clinical needs, delivering novel therapeutic approaches and reliable products to both healthcare providers and patients.

Leveraging the scalability and high efficiency of its four major technology platforms, Acotec has successively launched AcoArt Orchid, China’s first peripheral drug-coated balloon (DCB) product, centered on the “intervention without implantation” treatment approach.^®Dhalia™, the world’s first clinically validated infrapopliteal drug-coated balloon (DCB) products AcoArt Tulip™ & Litos™, China’s first thrombectomy aspiration system AcoStream™, and China’s first comprehensive radiofrequency ablation system, among others. To date, Acotec has established a pipeline of 36 products, offering endovascular minimally invasive interventional solutions for five major specialties: vascular surgery, cardiology, nephrology, neurology, and andrology.

Through this diversified product portfolio, Acotec will continue to revolutionize therapeutic approaches in the field of vascular intervention and combat vascular diseases. On its path to becoming a global leader in medical technology, the company is committed to delivering superior systemic vascular intervention solutions to physicians and patients worldwide, helping patients achieve long-term clinical benefits and improve their quality of life.

Boston Scientific is committed to innovating for life. We are dedicated to advancing medical solutions that improve the lives of patients around the world. For more than 40 years, Boston Scientific has led the development of the global medical technology industry by providing a broad portfolio of high-performance medical solutions that address the urgent therapeutic needs of a wide patient population and help reduce healthcare costs. For more information, please visit our website:www.bostonscientific.cn。

Disclaimer:

This press release contains forward-looking statements, which are based on PrioraMed’s current expectations, estimates, forecasts, opinions, and assumptions regarding the business and market operations of itself and its subsidiaries. These statements do not constitute a guarantee of future performance and are subject to market risks, uncertainties, and factors beyond PrioraMed’s control. Therefore, actual results or returns may differ materially from the assumptions made and statements contained in this press release.